Outbreak and impact of coronavirus disease 2019 (COVID-19) on dialysis patients; Al Khezam dialysis center experience, Kuwait

E. Abdallah, B. Al Helal, Reem Asad, G. Nessim, Shaikha Al-Bader, Y. Elsharkawi, A. Elmasry, Mohamed Fathy Mohamed Abdelgelil, Essam Allam, Sahar Abdelkareem, M. Kamal, Mohamed Hemida, Y. Shaaban, Zeinab Zeid, A. Saad, A. Ahmed
{"title":"Outbreak and impact of coronavirus disease 2019 (COVID-19) on dialysis patients; Al Khezam dialysis center experience, Kuwait","authors":"E. Abdallah, B. Al Helal, Reem Asad, G. Nessim, Shaikha Al-Bader, Y. Elsharkawi, A. Elmasry, Mohamed Fathy Mohamed Abdelgelil, Essam Allam, Sahar Abdelkareem, M. Kamal, Mohamed Hemida, Y. Shaaban, Zeinab Zeid, A. Saad, A. Ahmed","doi":"10.34172/jre.2021.14","DOIUrl":null,"url":null,"abstract":"Introduction: Coronavirus disease 2019 (COVID-19) is an outbreak due to SARS-CoV-2, declared by the World Health Organization (WHO) as a global pandemic in March 2020. Patients with underlying diseases, such as those with end-stage kidney disease (ESKD) on dialysis, are at greater risk. Objectives: The aim of our study to assess the outbreak and impact of COVID-19 on dialysis patients. Patients and Methods: Our study prospectively assessed and followed 442 patients with ESKD undergoing dialysis [390 patients on maintenance hemodialysis (HD) and 52 patients on peritoneal dialysis (PD)] for outbreak and impact of COVID-19 on these patients during the period from April 22, 2020 until March 23, 2021 in Al Khezam dialysis center, Kuwait. Age, gender, nationality, original kidney disease, history of hypertension (HTN), diabetes mellitus (DM), ischemic heart disease (IHD), congestive heart failure (CHF), bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), history of pulmonary embolism (PE) and source of infection were analyzed. Symptoms as fever, fatigue, cough, loss of smell and taste and chest pain were recorded, the need for ICU admission, mechanical ventilation (MV), extracorporeal membrane oxygenation (ECMO), medications were recorded. The need to shift to continuous renal replacement therapy (CRRT) and outcomes (complications and mortality) were analyzed. Results: Our study reported that 102 out of 442 (23%) dialysis patients [97 out of 390 (24.8%) HD patients and 5 out of 52 (9.6%) PD patients] got infected with COVID-19 and reinfection reported in 4 out of 97 (4%) COVID-19 HD patients. Around 27% of COVID-19 HD patients had fever, 19% had fatigue, 8% had cough, 4% had loss of smell, 4% had loss of taste, 4% had chest pain and 40% of COVID-19 PD patients had fever. Fifteen out of 97 (15 %) COVID-19 HD patients needed ICU admission, 12 out of 97 (12 %) COVID-19 HD patients needed MV. A 33 out of 97 (34%) COVID-19 HD patients and 4 out of 5 (80%) COVID-19 PD patients needed to switch to CRRT. Mortality was 17 (15 HD and 2 PD) out of 102 (16.6 %) COVID-19 dialysis patients and common causes of death were sepsis, myocardial infarction (MI), heart failure and PE. Conclusion: Outbreak and mortality of COVID-19 infection is high in ESKD patients undergoing dialysis compared with general populations. Strict protocol for prevention of COVID-19 should be undertaken in dialysis centers and encourage of home dialysis and highly protective COVID-19 vaccination priority for dialysis patients.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jre.2021.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is an outbreak due to SARS-CoV-2, declared by the World Health Organization (WHO) as a global pandemic in March 2020. Patients with underlying diseases, such as those with end-stage kidney disease (ESKD) on dialysis, are at greater risk. Objectives: The aim of our study to assess the outbreak and impact of COVID-19 on dialysis patients. Patients and Methods: Our study prospectively assessed and followed 442 patients with ESKD undergoing dialysis [390 patients on maintenance hemodialysis (HD) and 52 patients on peritoneal dialysis (PD)] for outbreak and impact of COVID-19 on these patients during the period from April 22, 2020 until March 23, 2021 in Al Khezam dialysis center, Kuwait. Age, gender, nationality, original kidney disease, history of hypertension (HTN), diabetes mellitus (DM), ischemic heart disease (IHD), congestive heart failure (CHF), bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), history of pulmonary embolism (PE) and source of infection were analyzed. Symptoms as fever, fatigue, cough, loss of smell and taste and chest pain were recorded, the need for ICU admission, mechanical ventilation (MV), extracorporeal membrane oxygenation (ECMO), medications were recorded. The need to shift to continuous renal replacement therapy (CRRT) and outcomes (complications and mortality) were analyzed. Results: Our study reported that 102 out of 442 (23%) dialysis patients [97 out of 390 (24.8%) HD patients and 5 out of 52 (9.6%) PD patients] got infected with COVID-19 and reinfection reported in 4 out of 97 (4%) COVID-19 HD patients. Around 27% of COVID-19 HD patients had fever, 19% had fatigue, 8% had cough, 4% had loss of smell, 4% had loss of taste, 4% had chest pain and 40% of COVID-19 PD patients had fever. Fifteen out of 97 (15 %) COVID-19 HD patients needed ICU admission, 12 out of 97 (12 %) COVID-19 HD patients needed MV. A 33 out of 97 (34%) COVID-19 HD patients and 4 out of 5 (80%) COVID-19 PD patients needed to switch to CRRT. Mortality was 17 (15 HD and 2 PD) out of 102 (16.6 %) COVID-19 dialysis patients and common causes of death were sepsis, myocardial infarction (MI), heart failure and PE. Conclusion: Outbreak and mortality of COVID-19 infection is high in ESKD patients undergoing dialysis compared with general populations. Strict protocol for prevention of COVID-19 should be undertaken in dialysis centers and encourage of home dialysis and highly protective COVID-19 vaccination priority for dialysis patients.
2019冠状病毒病(COVID-19)疫情对透析患者的影响科威特Al Khezam透析中心经验
简介:2019冠状病毒病(COVID-19)是由世界卫生组织(世卫组织)于2020年3月宣布为全球大流行的SARS-CoV-2引起的疫情。有基础疾病的患者,如透析的终末期肾病(ESKD)患者,风险更大。目的:本研究的目的是评估COVID-19对透析患者的爆发和影响。患者和方法:本研究前瞻性评估和随访了科威特Al Khezam透析中心2020年4月22日至2021年3月23日期间442例接受透析的ESKD患者[390例进行维持性血液透析(HD), 52例进行腹膜透析(PD)],以了解COVID-19对这些患者的爆发和影响。分析年龄、性别、民族、原发肾病、高血压(HTN)史、糖尿病(DM)史、缺血性心脏病(IHD)史、充血性心力衰竭(CHF)史、支气管哮喘(BA)史、慢性阻塞性肺疾病(COPD)史、肺栓塞(PE)史及感染源。记录患者发热、乏力、咳嗽、嗅觉和味觉丧失、胸痛等症状,记录是否需要入住ICU、是否需要机械通气、是否需要体外膜氧合、是否需要用药。我们分析了转向持续肾替代治疗(CRRT)的必要性和结果(并发症和死亡率)。结果:我们的研究报告了442例透析患者中102例(23%)[390例HD患者中97例(24.8%),52例PD患者中5例(9.6%)]感染了COVID-19, 97例COVID-19 HD患者中有4例(4%)报告了再感染。约27%的COVID-19 HD患者有发烧,19%有疲劳,8%有咳嗽,4%有嗅觉丧失,4%有味觉丧失,4%有胸痛,40%的COVID-19 PD患者有发烧。97例COVID-19 HD患者中有15例(15%)需要ICU, 97例COVID-19 HD患者中有12例(12%)需要MV。97名COVID-19 HD患者中有33名(34%)和5名COVID-19 PD患者中有4名(80%)需要切换到CRRT。在102例(16.6%)COVID-19透析患者中,死亡率为17例(15例HD和2例PD),常见死亡原因为败血症、心肌梗死(MI)、心力衰竭和PE。结论:透析患者中COVID-19感染的暴发和死亡率高于普通人群。透析中心应严格执行COVID-19预防方案,鼓励家庭透析,并优先为透析患者接种高保护性COVID-19疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信